IVIXF (Invion) Scaled Net Operating Assets: 0.67 (As of Dec. 2025)


IVIXF Invion Ltd IVIXF
16 GF Score
Price $0.04
GF Value $0.17
! 2 Warning Signs
View Full Analysis

What is Invion Scaled Net Operating Assets?

Invion IVIXF -83.23% 16 Scaled Net Operating Assets is 0.67 as of Dec. 2025. GuruFocus rates IVIXF with a GF Score™ of 16/100 and a GF Value™ of $0.17. The stock has 2 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Invion's operating assets for the quarter that ended in Dec. 2025 was $5.28 Mil. Invion's operating liabilities for the quarter that ended in Dec. 2025 was $1.17 Mil. Invion's Total Assets for the quarter that ended in Jun. 2025 was $6.18 Mil. Therefore, Invion's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was 0.67.


Invion Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Invion's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invion Scaled Net Operating Assets Chart

Invion Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.72 1.81 0.68 0.71 0.47

Invion Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.83 0.74 0.77 0.55 0.67

IVIXF vs ZTS, UTHR: Scaled Net Operating Assets Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Invion's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Invion Scaled Net Operating Assets vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Invion's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Invion's Scaled Net Operating Assets falls into.


IVIXF
16GF Score
Invion Ltd IVIXF
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Invion Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Invion's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Jun. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Jun. 2025 )
=(Operating Assets (A: Jun. 2025 )-Operating Liabilities (A: Jun. 2025 ))/Total Assets (A: Jun. 2024 )
=(5.625-0.806)/10.26
=0.47

where

Operating Assets(A: Jun. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=6.178 - 0.553
=5.625

Operating Liabilities(A: Jun. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=0.806 - 0 - 0
=0.806

Invion's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2025 )
=(Operating Assets (Q: Dec. 2025 )-Operating Liabilities (Q: Dec. 2025 ))/Total Assets (Q: Jun. 2025 )
=(5.282-1.166)/6.178
=0.67

where

Operating Assets(Q: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=5.374 - 0.092
=5.282

Operating Liabilities(Q: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=1.583 - 0 - 0.417
=1.166

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.67 mean?
Invion (IVIXF) has a Scaled Net Operating Assets of 0.67 as of Dec. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Invion and its competitors.
Is Invion's Scaled Net Operating Assets too high?
Invion's current Scaled Net Operating Assets is 0.67. Overall, Invion has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Invion's Scaled Net Operating Assets compare to ZTS and UTHR?
Invion's Scaled Net Operating Assets of 0.67 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Drug Manufacturers company?
A good Scaled Net Operating Assets depends on the Drug Manufacturers industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Invion and its competitors. Invion's current Scaled Net Operating Assets is 0.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invion stock overvalued right now?
Invion (IVIXF) has a current Scaled Net Operating Assets of 0.67. The stock's GF Value™ is $0.17, compared to a current price of $0.04 — trading 78.3% below its estimated fair value. The current Scaled Net Operating Assets is 0.67. Invion's overall GF Score™ is 16/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Invion (IVIXF), the current Scaled Net Operating Assets is 0.67 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Invion (IVIXF) Overvalued in 2026?

Based on GuruFocus' analysis, Invion stock appears to be undervalued. The current stock price of $0.04 is trading 78.3% below its estimated GF Value™ of $0.17.

Key valuation signals for IVIXF:

  • Scaled Net Operating Assets: 0.67
  • GF Value™: $0.17 vs. price of $0.04 (78.3% below fair value)
  • GF Score™: 16/100 with 2 warning signs

No single metric tells the full story. See the IVIXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Invion Business Description

Other Exchanges 7C8:GermanyIVX:Australia
Address 692 High Street, East Kew, VIC, AUS, 3102
Invion Ltd is an Australian clinical-stage pharmaceutical drug development company. It is engaged in the development of PhotoDynamic Therapy (PDT) for cancer treatments called Photosoft, for the treatment of a range of cancers, and infectious diseases. The company produces topical and intravenous products suitable for use in skin cancer and solid tumors, such as ovarian, prostate, and lung cancer. Invion has developed a portfolio of patent protected compounds. Its drug candidate is INV043, a novel photosensitiser which has the potential to work as a therapy and a diagnostic tool.
16GF Score

Get the complete analysis for IVIXF

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.04
Price
$0.17
GF Value